Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H42N4O5 |
Molecular Weight | 490.6355 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N
InChI
InChIKey=LBGFKUUHOPIEMA-PEARBKPGSA-N
InChI=1S/C26H42N4O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-23(32)28-22-16-17-30(26(34)29-22)25-20(18-27)24(33)21(19-31)35-25/h16-17,20-21,24-25,31,33H,2-15,19H2,1H3,(H,28,29,32,34)/t20-,21+,24-,25+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22739266 |
https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C82697 |
https://www.cyclacel.com/research_programs_oncology_cyc682.shtmlhttps://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-announces-fda-orphan-drug-designation | https://www.ncbi.nlm.nih.gov/pubmed/26523431 | https://www.ashclinicalnews.org/online-exclusives/sapacitabine-fails-to-meet-primary-endpoint-in-clinical-trial-of-older-aml-patients/
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22739266 |
https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C82697 |
https://www.cyclacel.com/research_programs_oncology_cyc682.shtmlhttps://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-announces-fda-orphan-drug-designation | https://www.ncbi.nlm.nih.gov/pubmed/26523431 | https://www.ashclinicalnews.org/online-exclusives/sapacitabine-fails-to-meet-primary-endpoint-in-clinical-trial-of-older-aml-patients/
Sapacitabine (also known as CYC-682) is an orally bioavailable 2′-deoxycytidine analog that is in clinical trials for hematologic malignancies and solid tumors. Sapacitabine is primarily metabolized by plasma, gut and liver amidases into the active metabolite CNDAC. This metabolite is subsequently transported inside cells and then phosphorylated by deoxycytidine kinase (dCK) into CNDAC triphosphate before being incorporated into cellular DNA. Sapacitabine participated in phase III clinical in older patients with acute myeloid leukemia (AML); however, it failed to meet its primary endpoint of the statistically significant improvement in overall survival (OS). The drug has been also involved in phase II clinical trials for the treatment of patients with myelodysplastic syndromes, cutaneous T-cell lymphoma, and non-small cell lung cancer. In addition, in combination with olaparib the drug was studied in phase I/II trial as a possible treatment for breast cancer with a BRCA mutation. On July 1, 2010, Cyclacel Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s sapacitabine for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612780 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17402726 |
0.13 µM [IC50] | ||
Target ID: DNA Sources: https://www.ncbi.nlm.nih.gov/pubmed/22739266 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01303796
oral sapacitabine capsules
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/08/557
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
||
|
FDA ORPHAN DRUG |
263508
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
||
|
NCI_THESAURUS |
C1557
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
||
|
FDA ORPHAN DRUG |
263408
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C117959
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
DB06365
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
8672
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
100000156608
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
SAPACITABINE
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
W335P73C3L
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
151823-14-2
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
WW-161
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
153970
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105681
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
DTXSID90164887
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
145429
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
SUB130529
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY | |||
|
C64541
Created by
admin on Sat Dec 16 17:56:16 GMT 2023 , Edited by admin on Sat Dec 16 17:56:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD